Novavax, Inc. (NVAX) SEC Filings & Earnings Calls

Activist/insider selling and structural change

“Shah Capital Fund LLC: As of October 5, 2026, the total shares sold were 2,870,000 at an average price of $11.3486.” · word for word

Dependence on Sanofi partnership for revenue and milestones; regulatory approval risks.

“Sanofi confirmed with Novavax they are in advanced discussions with regulators regarding their Phase 3 COVID-19-Influenza Combination trial timing”

Dependence on partners for commercialization

“Sanofi leads commercialization efforts for our COVID-19 Vaccine (Nuvaxovid™).” · word for word

Regulatory and clinical trial uncertainty

“After consultation with the U.S. FDA, we determined that seeking an accelerated approval pathway for our CIC and stand-alone influenza candidates would not be feasible.” · word for word

COVID vaccine revenue collapse post-APA close-out

“Nuvaxovid sales $10M vs $608M prior year (98% decline) due to close-out of APA agreements.”

Dependence on licensing partnerships for future revenue

“Revenue increasingly reliant on upfront payments and milestones from Matrix-M licensing deals; product sales minimal.”

Dependence on partnerships for commercialization

“Sanofi will lead commercialization efforts for our COVID-19 Vaccine” · word for word

Regulatory and clinical trial risks

“We determined that seeking an accelerated approval pathway for our CIC and stand-alone influenza candidates would not be feasible.” · word for word

Dependence on partnership milestones for revenue

“The 2025 Objectives included 'Close Additional Business Development Deals' which was only partially met (23% achievement), indicating reliance on future partnerships.”

Execution risk in business development

“The objective 'Close Additional Business Development Deals' was only partially met at 23%, showing challenges in closing new partnerships.”

Key executive turnover

“Effective June 20, 2025, Mr. Trizzino's employment as President and Chief Operating Officer terminated due to the elimination of the position of Chief Operating Officer. ... effective March 27, 2026, Dr. Draghia-Akli's employment as Executive Vice President, Research and Development was terminated as an Involuntary Termination without Cause.” · word for word

Activist pressure on board and strategy

“On April 8, 2026, the Reporting Persons sent a letter ... declaring a notice of intention to vote against Board Nominees and Executive Compensation.” · word for word

Activist pressure on board and strategy

“On April 8, 2026, the Reporting Persons sent a letter ... declaring a notice of intention to vote against Board Nominees and Executive Compensation.” · word for word

Australia APA Refund Risk

“In the event that we do not, on or before the relevant contractual deadlines, receive regulatory approval for, and deliver, the seasonally updated COVID-19 Vaccine, up to $92.5 million of deferred revenue may become refundable.” · word for word

Going Concern Uncertainty

“We believe our cash, cash equivalents, and marketable securities as of December 31, 2025, together with cash expected to be generated from product sales and licensing, royalties and other revenue, will be sufficient to enable us to fund our projected operations and capital expenditures through at least the next 12 months.”

Dependence on Sanofi Partnership

“As we evolve our operating model to focus on our partnership with Sanofi, the development of our late-stage pipeline... we expect to continue to incur significant operating expenses and anticipate significant losses over time.” · word for word

Dependence on partnership milestones and royalties for revenue; product sales volatility.

“Nuvaxovid sales declined from $50M Q4 2024 to $20M Q4 2025; Sanofi revenue down 16% YoY.”

Pipeline still early-stage; no clinical data until at least 2027.

“Novavax intends to enter the clinic with at least one program as early as 2027.” · word for word

Dependence on Pfizer's development and commercialization success; milestone and royalty payments uncertain.

“Pfizer's ability to successfully develop or commercialize vaccine products” · word for word

Dependence on Sanofi partnership for revenue and development

“Company's near-term revenue and pipeline advancement heavily rely on Sanofi collaboration; any disruption could materially impact operations.”

Uncertainty in COVID-19 vaccine demand and seasonality

“Shift to seasonal market and reliance on Sanofi for commercialization introduces demand uncertainty.”

Regulatory and clinical development risks for pipeline candidates

“CIC and flu candidates not on accelerated path; pediatric indication requires additional study; PMC trial required.”

Revenue concentration risk: Nuvaxovid sales declining as Sanofi takes over; reliance on partnership milestones.

“Nuvaxovid Sales of $0 in Q3 2025 vs $38M in Q3 2024; Sanofi revenue $48M vs $36M.”

Restructuring risk: Maryland site consolidation with $97M impairment charge.

“$97 million asset impairment related to the Maryland site consolidation transactions.” · word for word

Dependence on Sanofi partnership for future milestones and royalties; limited control over commercialization.

“Novavax is eligible to receive additional future milestones and royalties under the CLA related to Nuvaxovid, combination products developed by Sanofi using Nuvaxovid and new vaccines created by Sanofi utilizing Novavax’s Matrix-M ® adjuvant.” · word for word